<DOC>
	<DOCNO>NCT02523300</DOCNO>
	<brief_summary>To explore potential prognostic effect glucocorticoid postoperative aorta-related adverse event aortic dissection patient underwent thoracic endovascular aortic repair ( TEVAR ) , glucocorticoid ( 30mg/kg ) intravenously give within 2h TEVAR .</brief_summary>
	<brief_title>Glucocorticoid Prognosis TEVAR</brief_title>
	<detailed_description>This prospective , open , single-center , randomize control trial . Number patient : 240 patient include undertaken TEVAR.About 120 patient give glucocorticoid within 2h TEVAR experimental group , 120 patient give saline control group . Follow-up : 1. aortic compute tomographic angiography ( CTA ) examination 6 , 12 24 month TEVAR ; 2. telephone clinical follow-up 1 , 2 , 3 , 6 , 12 24 month . Primary outcome measure : aorta-related adverse event . Second outcome measure : 30-day mortality TEVAR , success rate endovascular repair , drug-related adverse event .</detailed_description>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<criteria>1. age 18 80 , male unpregnant female ; 2. diagnose aortic dissection , exclude intramural hematoma penetrate aortic ulcer ; 3. complicate aortic dissection definite indication TEVAR ; 4. voluntarily sign informed consent form ; 5. good compliance instruction cooperate followup . 1. appropriate vessel approach ; 2. patient connective tissue disease ( Marfan syndrome ) ; 3. patient endocrine disease , diabetes mellitus , undergoing hormonotherapy ; 4. bad compliance instruction followup ; 5. allergic nitinol contrast medium ; 6. estimate life expectancy le 24 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>